As CD20 is expressed on IgM-bearing pre-B ... Pure red cell aplasia with anti-erythropoietin antibodies Pure red cell aplasia can develop as a result of therapy with certain recombinant forms ...

most antibody-producing cells, or their malignant counterparts. As immature B cells expressing autoreactive antigen receptors are not depleted by anti-CD20 mAb, a new strategy for eliminating ...

IDEC Pharmaceuticals’s initial customized approach was circumvented by the work to develop anti-CD20 antibodies. Like other researchers, they derived their monoclonal antibodies from mice. So, to ...

The active full-length CD20 proteins feature both big and small ECD loops and bind anti-CD20 antibodies with high binding affinity in SPR and ELISA assay. The company offers various kinds of CD20 ...

Antibodies against B cells Rituximab is a depleting antibody directed against CD20 on the surface of B cells, which has established benefit in RA both with regards to clinical efficacy and ...

Therapeutic monoclonal antibodies (mAbs) are used in chronic lymphocytic leukemia immunotherapies to target the receptor CD20 at the plasma membrane of immunological B cells. Although they have ...

Research found that ibrutinib reduces red blood cell aggregation in patients with chronic lymphocytic leukemia (CLL), while ...

Noting that the combination involved both anti-CD19 and anti-CD20 monoclonal antibodies, press briefing moderator Mikkael Sekeres, MD, MS, of the Sylvester Comprehensive Cancer Center at the ...

An additional anti-CD20 antibody fragment directly targets the cancer. By design, the molecule possesses an interleukin-2 variant that triggers natural killer cell proliferation without activating ...

Depleting B cells with targeted antibodies such as rituximab (anti-CD20 mAb) is an established treatment for several autoimmune diseases, however, many patients have inadequate response to these ...